84 related articles for article (PubMed ID: 31261439)
1. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G; Kimura M; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Maehara O; Shimazaki T; Morikawa K; Natsuizaka M; Ogawa K; Sakamoto N
Hepatol Res; 2019 Nov; 49(11):1275-1285. PubMed ID: 31261439
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
[TBL] [Abstract][Full Text] [Related]
4. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
[TBL] [Abstract][Full Text] [Related]
5. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
6. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Tao W; Gan T; Lu J; Zhong J
Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
[TBL] [Abstract][Full Text] [Related]
7. Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production.
Murayama A; Sugiyama N; Suzuki R; Moriyama M; Nakamura N; Mochizuki H; Wakita T; Kato T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928005
[TBL] [Abstract][Full Text] [Related]
8. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.
Peiffer KH; Sommer L; Susser S; Vermehren J; Herrmann E; Döring M; Dietz J; Perner D; Berkowski C; Zeuzem S; Sarrazin C
Hepatology; 2016 Jan; 63(1):63-73. PubMed ID: 26406534
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Wang Y; Rao HY; Xie XW; Wei L
Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
Izhari MA
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835845
[TBL] [Abstract][Full Text] [Related]
11. Management of HCV patients in cases of direct-acting antiviral failure.
Hayes CN; Imamura M; Chayama K
Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):839-848. PubMed ID: 31392907
[No Abstract] [Full Text] [Related]
12. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
Ito J; Suda G; Yamamoto Y; Nagasaka A; Furuya K; Kumagai K; Kikuchi H; Miyagishima T; Kobayashi T; Kimura M; Yamasaki K; Umemura M; Izumi T; Tsunematsu S; Sato F; Tsukuda Y; Terashita K; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
Hepatol Res; 2016 Dec; 46(13):1294-1303. PubMed ID: 26896756
[TBL] [Abstract][Full Text] [Related]
14. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
[TBL] [Abstract][Full Text] [Related]
15. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
Sato K; Uraoka T
World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy.
Itakura J; Kurosaki M; Takada H; Nakakuki N; Matsuda S; Gondou K; Asano Y; Hattori N; Itakura Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Tsuchiya K; Nakanishi H; Takahashi Y; Maekawa S; Enomoto N; Izumi N
Hepatol Res; 2015 Oct; 45(10):E115-21. PubMed ID: 25564756
[TBL] [Abstract][Full Text] [Related]
17. Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank.
Kliemann DA; Tovo CV; Gorini da Veiga AB; Machado AL; West J
PLoS One; 2016; 11(8):e0159924. PubMed ID: 27504952
[TBL] [Abstract][Full Text] [Related]
18. Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance.
Douglas MW; Tay ESE; Wang DS; Ong ATL; Wilson C; Phu A; Kok J; Dwyer DE; Bull RA; Lloyd AR; Applegate TL; Dore GJ; Howe AY; Harrigan R; George J
Hepatol Commun; 2020 Jun; 4(6):904-915. PubMed ID: 32490325
[TBL] [Abstract][Full Text] [Related]
19. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
[TBL] [Abstract][Full Text] [Related]
20. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
